Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03947749 · ClinicalTrials.gov registry record
Linking Epigenomics With Prescription Opioid Abuse and High Impact Musculoskeletal Pain
A clinical trial, sponsored by University of Florida.
- Completed
- Registry status
- 275
- Enrollment target
NCT03947749 is a clinical trial that has completed, run by University of Florida. The registered enrollment target is 275 participants.
The verdict
NCT03947749 has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- 275 participants
- Enrollment target
Study Summary
Genetic variability from epigenetic modification of genes related to pain physiology and opioid pharmacodynamics may influence susceptibility to high-impact chronic musculoskeletal pain, opioid efficacy, and vulnerability to opioid abuse. Exploring the role of epigenomics and opioid addiction may improve understanding and treatment of these complex multifactorial conditions and, potentially, reduce their development.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 275 participants |
| Start Date | 2019-09-25 |
| Est. Completion | 2023-04-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03947749
The ClinicalTrials.gov registry entry for NCT03947749 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 275 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03947749 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03947749 about?
NCT03947749 is a clinical study titled "Linking Epigenomics With Prescription Opioid Abuse and High Impact Musculoskeletal Pain". Genetic variability from epigenetic modification of genes related to pain physiology and opioid pharmacodynamics may influence susceptibility to high-impact chronic musculoskeletal pain, opioid efficacy, and vulnerability to opioid abuse. Exploring the role of epigenomics and opioid addiction may im...
What is the current status of trial NCT03947749?
This trial is currently completed. The enrollment target is 275 participants. The study started on 2019-09-25. Estimated completion is 2023-04-06.
Who is sponsoring clinical trial NCT03947749?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.